MedPath

Samsung Bioepis AU Pty Ltd

🇦🇺Australia
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

15

TGA:15

Drug Approvals

OSPOMYV denosumab 60mg/1mL solution for injection pre-filled syringe (445963)

Product Name
OSPOMYV denosumab 60mg/1mL solution for injection pre-filled syringe
Approval Date
Jul 9, 2025
TGA

EPYZTEK ustekinumab 90 mg/1 mL solution for injection pre-filled syringe (423024)

Product Name
EPYZTEK ustekinumab 90 mg/1 mL solution for injection pre-filled syringe
Approval Date
Oct 21, 2024
TGA

EPYZTEK ustekinumab 5 mg/1 mL solution for intravenous infusion injection vial (423023)

Product Name
EPYZTEK ustekinumab 5 mg/1 mL solution for intravenous infusion injection vial
Approval Date
Oct 21, 2024
TGA

EPYZTEK ustekinumab 45 mg/0.5mL solution for injection pre-filled syringe (423022)

Product Name
EPYZTEK ustekinumab 45 mg/0.5mL solution for injection pre-filled syringe
Approval Date
Oct 21, 2024
TGA

ONBEVZI bevacizumab 100 mg/4mL concentrated injection for intravenous infusion vial (431837)

Product Name
ONBEVZI bevacizumab 100 mg/4mL concentrated injection for intravenous infusion vial
Approval Date
Jan 24, 2024
TGA

ONBEVZI bevacizumab 400 mg/16mL concentrated injection for intravenous infusion vial (431838)

Product Name
ONBEVZI bevacizumab 400 mg/16mL concentrated injection for intravenous infusion vial
Approval Date
Jan 24, 2024
TGA

HADLIMA adalimumab 40 mg/0.4 mL solution for injection in pre-filled syringe (385133)

Product Name
HADLIMA adalimumab 40 mg/0.4 mL solution for injection in pre-filled syringe
Approval Date
Feb 15, 2023
TGA

HADLIMA adalimumab 40 mg/0.4 mL solution for injection in PushTouch auto-injector (384975)

Product Name
HADLIMA adalimumab 40 mg/0.4 mL solution for injection in PushTouch auto-injector
Approval Date
Feb 15, 2023
TGA

BYOOVIZ ranibizumab 10 mg/mL solution for injection vial (375304)

Product Name
BYOOVIZ ranibizumab 10 mg/mL solution for injection vial
Approval Date
Aug 24, 2022
TGA

ONTRUZANT trastuzumab 150 mg powder for injection vial (298457)

Product Name
ONTRUZANT trastuzumab 150 mg powder for injection vial
Approval Date
Jan 9, 2019
TGA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.